Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,653,581
  • Shares Outstanding, K 27,851
  • Annual Sales, $ 0 K
  • Annual Income, $ -303,270 K
  • EBIT $ -326 M
  • EBITDA $ -330 M
  • 60-Month Beta 2.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.91

Options Overview Details

View History
  • Implied Volatility 68.94% (-2.53%)
  • Historical Volatility 42.48%
  • IV Percentile 7%
  • IV Rank 6.49%
  • IV High 177.65% on 07/01/25
  • IV Low 61.39% on 02/19/26
  • Expected Move (DTE 11) 30.56 (9.89%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 101
  • Volume Avg (30-Day) 226
  • Put/Call OI Ratio 3.68
  • Today's Open Interest 9,570
  • Open Int (30-Day) 9,801
  • Expected Range 278.45 to 339.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -3.35
  • Number of Estimates 5
  • High Estimate -3.00
  • Low Estimate -3.64
  • Prior Year -3.29
  • Growth Rate Est. (year over year) -1.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
291.17 +6.13%
on 03/09/26
356.00 -13.20%
on 02/24/26
-10.53 (-3.30%)
since 02/09/26
3-Month
251.00 +23.11%
on 12/10/25
356.00 -13.20%
on 02/24/26
+50.88 (+19.71%)
since 12/09/25
52-Week
26.70 +1,057.34%
on 04/09/25
356.00 -13.20%
on 02/24/26
+270.51 (+702.62%)
since 03/07/25

Most Recent Stories

More News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S....

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 309.01 (-0.55%)
Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 309.01 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 363.68
2nd Resistance Point 345.61
1st Resistance Point 327.31
Last Price 309.01
1st Support Level 290.94
2nd Support Level 272.87
3rd Support Level 254.57

See More

52-Week High 356.00
Last Price 309.01
Fibonacci 61.8% 230.21
Fibonacci 50% 191.35
Fibonacci 38.2% 152.49
52-Week Low 26.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar